Stephen W. Fesik
Molecular Biology · 1999–2016
A researcher in the Science corpus: 11 papers; trusts 5 researchers and is trusted by 14 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 117 citations into it; #3,650 of 17,773 by trust here, #1,770 by citations
- Oncology — 33 citations into it; #269 of 1,698 by trust here, #837 by citations
- Immunology — 14 citations into it
Whom Stephen W. Fesik trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Stephen W. Fesik overall
- Jerry M. Adams
- R. Youle
- Matthew Vanneman
- P. Mehlen
- G. Lessene
- Ricky W. Johnstone
- Robin Mathew
- D. Altieri
- Suzanne Cory
- A. Strasser
Papers from Stephen W. Fesik's perspective
Ordered by how strongly the researchers Stephen W. Fesik trusts endorse each paper. Same corpus, a different order for every researcher.
- Structural and biochemical basis of apoptotic activation by Smac/DIABLO (Nature)
- Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. (Cell)
- Structural basis of IAP recognition by Smac/DIABLO (Nature)
- Promoting apoptosis as a strategy for cancer drug discovery (Nature Reviews. Cancer)
- An inhibitor of Bcl-2 family proteins induces regression of solid tumours (Nature)
- BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. (Genes & Development)
- Targeting death and decoy receptors of the tumour-necrosis factor superfamily (Nature Reviews. Cancer)
- Structural basis for phosphoserine-proline recognition by group IV WW domains (Nature Structural Biology)
- From bench to clinic with apoptosis-based therapeutic agents (Nature)
- ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling.
Their papers
- An inhibitor of Bcl-2 family proteins induces regression of solid tumours (2005) — 3,422 citations
- Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain (2000) — 666 citations
- Promoting apoptosis as a strategy for cancer drug discovery (2005) — 1,022 citations
- 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. (2000) — 653 citations
- Drugging the undruggable Ras: mission possible? (2014) — 1,780 citations
- Structural basis for the inhibition of caspase-3 by XIAP. (2001) — 797 citations
- Structural biology of the Bcl-2 family of proteins. (2004) — 765 citations
- ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. (2008) — 1,864 citations
- NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups (2000) — 192 citations
- Twenty years on: the impact of fragments on drug discovery (2016) — 798 citations
- Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. (1999)